Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lilly Announces Detailed Results of the Phase 3 Solanezumab EXPEDITION
http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=711933
October 8, 2012
Lilly Announces Detailed Results of the Phase 3 Solanezumab EXPEDITION Studies Following a Presentation of the Independent Analyses by the Alzheimer's Disease Cooperative Study (ADCS)
INDIANAPOLIS, Oct. 8, 2012 /PRNewswire/ --
Lilly's analysis, as previously reported, showed primary endpoints, both cognitive and functional, were not met in the two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in patients with mild-to-moderate Alzheimer's disease
In Lilly's pre-specified secondary analysis of pooled data in patients with mild Alzheimer's disease, a statistically significant slowing of cognitive decline was shown; this finding represented a 34 percent reduction in decline
Independent analyses of EXPEDITION studies conducted by the ADCS were generally similar to Lilly's top-line results reported on August 24, 2012
Next steps for solanezumab will be determined after discussions with regulators
Eli Lilly and Company (NYSE: LLY) today announced its detailed results for the Phase 3, double-blind, placebo-controlled EXPEDITION studies in patients with mild-to-moderate Alzheimer's disease. This announcement follows the presentation of results from independent analyses of the EXPEDITION study data conducted by the Alzheimer's Disease Cooperative Study (ADCS), an academic research consortium, at the annual meeting of the American Neurological Association (ANA) by Rachelle Doody, M.D., Ph.D., professor of Neurology and the Effie Marie Cain Chair in Alzheimer's Disease Research, Baylor College of Medicine. Dr. Doody is a member of the steering committee for the ADCS.
Lilly provided the raw data (the full data set collected from the EXPEDITION studies) to the ADCS. The ADCS statisticians then performed independent analyses of these data. These results were presented at today's meeting.
"Alzheimer's disease research has been extremely challenging," said Dr. Doody. "The data results from the solanezumab Phase 3 trials were encouraging to the ADCS team. These results represent an important step for the medical, academic, and scientific communities in understanding brain amyloid as a target of AD therapies."
Lilly's relationship with the ADCS is longstanding and the decision to have them conduct independent analyses of the Phase 3 solanezumab data was made prior to seeing the top-line results from either of the EXPEDITION studies.
Lilly Results from EXPEDITION1
The EXPEDITION1 study was designed with co-primary cognitive and functional endpoints (the Alzheimer's Disease Assessment Scale- Cognitive subscale [ADAS-Cog11] and the Alzheimer's Disease Cooperative Study-Activities of Daily Living [ADCS-ADL], respectively) in patients with mild-to-moderate Alzeimer's disease.
Lilly's pre-specified secondary analyses showed that results in patients with mild Alzheimer's disease taking solanezumab demonstrated a slowing of cognitive decline compared with placebo (p=.008), as measured by the ADAS- Cog11. This finding represented a 42 percent reduction in decline at the endpoint of the 18-month study. The difference in functional decline (ADCS-ADL) was not statistically significant.
Lilly Results from EXPEDITION2
Based on the results of EXPEDITION1, Lilly modified the statistical analysis plan (SAP) for EXPEDITION2, prior to database lock, to specify a single primary endpoint of cognition in patients with mild Alzheimer's disease as measured by the ADAS-Cog14, a 14-item scale, which includes three additional items considered relevant for patients with mild Alzheimer's disease.1 At the conclusion of EXPEDITION2, there was a 20 percent reduction in cognitive decline in patients with mild Alzheimer's disease taking solanezumab; however, the treatment difference was not statistically significant (p=.120). In the pre-specified secondary endpoint of ADCS-ADL, there was a 19 percent reduction in functional decline in patients with mild Alzheimer's disease treated with solanezumab, as compared with placebo; this difference was not statistically significant (p=.076).
Lilly Results from Pooled Analyses of EXPEDITION1 and EXPEDITION2
A pre-specified secondary analysis of pooled data in patients with mild Alzheimer's disease showed a slowing of cognitive decline (p=.001) compared with placebo, as measured by the ADAS-Cog14; this finding represented a 34 percent reduction in decline. In addition, the secondary analysis of the pooled data in patients with mild Alzheimer's disease showed a 17 percent reduction of functional decline as measured by the ADCS-ADL; however, the treatment difference was not statistically significant compared with placebo (p=.057).
A number of different biomarkers were assessed in the EXPEDITION studies. Some, but not all, of these biomarkers showed an effect of solanezumab. These additional data will be presented by the ADCS at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in Monte Carlo, Monaco, on October 29, 2012, or at subsequent medical meetings and in appropriate scientific venues.
In the EXPEDITION studies, the only adverse event with an incidence of at least 1 percent that occurred statistically significantly more in the solanezumab group than in the placebo group was angina (1.1 percent versus 0.2 percent). The incidence of vasogenic edema (ARIA-E) was approximately 1 percent, occurring in 11 patients treated with solanezumab and 5 patients on placebo, which was not statistically significant.
"This is a complex disease that touches millions of people worldwide," said David Ricks, senior vice president and president, Lilly Bio-Medicines. "Alzheimer's disease causes significant burden on patients, caregivers and our society. While the path forward has not been determined, we believe these data in patients with mild disease may provide a step toward a potential treatment option."
About the Primary Endpoint Scales2
The ADAS-Cog is a standard tool used in pivotal clinical trials to detect therapeutic efficacy in cognition. It consists of subtests related to memory, praxis, and language. Higher scores on the ADAS-Cog indicate more cognitive impairment. The ADCS-ADL measures activities of daily living, such as reading books or magazines, pastime activities, or household chores. Higher scores on the ADCS-ADL indicate less functional impairment.
About the EXPEDITION Trials
The EXPEDITION trials consisted of two Phase 3, double-blind, placebo-controlled solanezumab trials in patients with mild-to-moderate Alzheimer's disease in 16 countries around the world. In both of the EXPEDITION study protocols, mild Alzheimer's disease was defined as a baseline Mini-Mental Status Examination (MMSE) score of 20 to 26 and moderate Alzheimer's disease was defined as a baseline MMSE score of 16 to 19.
The designs of EXPEDITION1 and EXPEDITION2 were the same. Patients aged 55-94 years were eligible to enroll in these studies; EXPEDITION1 enrolled 1,012 patients and EXPEDITION2 enrolled 1,040 patients. Patients received either 400mg of solanezumab infused intravenously (IV) or placebo every four weeks for approximately 18 months. Both EXPEDITION trials allowed patients to remain on stable standard of care (defined as their existing treatment regimen) during these studies. More than 85 percent of the patients in these trials were taking an acetycholinesterase inhibitor and / or memantine.
About Alzheimer's disease
Alzheimer's disease, the most common form of dementia, causes progressive decline in memory and other aspects of cognition.3,4 Researchers do not know exactly what causes Alzheimer's disease and there are currently no approved treatments shown to slow the progression of this devastating disease, only treatment options that reduce certain symptoms of the disease.2,3,5 Alzheimer's Disease International (ADI) estimates that there are currently 35.6 million people with dementia worldwide, with 7.7 million new cases each year (which implies one new case every four seconds).6 The number of people affected is estimated to be over 115 million by 2050.4 Estimates vary, but experts suggest that as many as 5.4 million Americans may have Alzheimer's disease.3
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers — through medicines and information — for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. P-LLY
This press release contains certain forward-looking statements about solanezumab. This release reflects Lilly's current beliefs; however, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date, or that solanezumab will be approved as a product or will prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
1 Mohs R, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ, and the Alzheimer's Disease Cooperative Study. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broadens its scope. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S13-S21.
2 Robert P, Ferris S, Gauthier S, Ihl R, Winblad B, Tennigkeit F. Review of Alzheimer's disease Scales: Is There a Need for a New Multi-domain Scale for Therapy Evaluation in Medical Practice?. Alzheimer's Research & Therapy. 2010; 2(24): 1-13.
3 National Institute of Neurological Disorders and Stroke. "Dementia: Hope Through Research." Available at: http://www.ninds.nih.gov/disorders/dementias/detail_dementia.htm#1908919213. Accessed on August 13, 2012.
4 Alzheimer's Association. "2012 Alzheimer's Disease Facts and Figures." Available at: http://www.alz.org/downloads/facts_figures_2012.pdf. Accessed on August 13, 2012.
5 Perrin, R., et al. "Multimodal techniques for diagnosis and prognosis of Alzheimer's disease." Nature 2009 (461); 916-922.
6 Alzheimer's Disease International. "Dementia Statistics." Available at: http://www.alz.co.uk/research/statistics. Accessed on August 13, 2012.
(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )
SOURCE Eli Lilly and Company
News Provided by Acquire Media
From the prospectus-
· Each Holder agreed not to convert more than 20% of such Holder’s outstanding principal amount of Amended and Restated Debenture in any month during the period from September 1, 2009 through January 31, 2010, provided, however, that this limitation will terminate if (i)(a) the volume weighted average price of the Company’s common stock for each of 5 consecutive trading days is greater than $0.15 per share, and (b) the trading volume on such days exceeds 7,500,000 shares per trading day, or (ii)(a) the volume weighted average price for any one trading day is greater than $0.20 per share and (b) the trading volume on such day exceeds 10,000,000 shares.
Looks like conversion exception (a) can be met right now:
a) the volume weighted average price of the Company’s common stock for each of 5 consecutive trading days is greater than $0.15 per share, and (b) the trading volume on such days exceeds 7,500,000 shares per trading day,
Date Open High Low Close Volume Adj Close*
Dec 23, 2010 0.23 0.23 0.17 0.20 86,014,000 0.20
Dec 22, 2010 0.26 0.26 0.20 0.22 71,620,400 0.22
Dec 21, 2010 0.24 0.27 0.24 0.26 87,067,900 0.26
Dec 20, 2010 0.20 0.23 0.20 0.23 58,492,300 0.23
Dec 17, 2010 0.18 0.21 0.18 0.20 46,121,300 0.20
Dec 16, 2010 0.16 0.18 0.16 0.18 29,689,500 0.18
Dec 15, 2010 0.14 0.16 0.11 0.16 42,183,400 0.16
Dec 14, 2010 0.14 0.14 0.14 0.14 22,946,800 0.14
Dec 13, 2010 0.16 0.16 0.13 0.13 39,817,900 0.13
Dec 10, 2010 0.17 0.18 0.16 0.16 30,703,100 0.16
Dec 9, 2010 0.15 0.17 0.15 0.17 55,139,900 0.17
Dec 8, 2010 0.17 0.20 0.14 0.15 143,206,000 0.15
Dec 7, 2010 0.14 0.16 0.13 0.16 61,794,200 0.16
Dec 6, 2010 0.11 0.14 0.10 0.13 59,723,200 0.13
Dec 3, 2010 0.09 0.11 0.09 0.11 24,503,500 0.11
Dec 2, 2010 0.08 0.09 0.08 0.09 22,784,900 0.09
Dec 1, 2010 0.10 0.10 0.08 0.08 30,957,900 0.08
http://finance.yahoo.com/q/hp?s=ACTC.OB&a=08&b=17&c=2010&d=11&e=27&f=2010&g=d
My question is regarding the following verbage- "this limitation will terminate if...". Does this mean that once market conditions meet the exception (either a or b) that there will never be any further requirement for sellers to abide by the original agreement not to convert more than 20% of such Holder’s outstanding principal amount in any month? Or, will that agreement come back into play if the market stops meeting the exception clauses?
TIA
Here is background info on the point of contact for those jobs:
Allen Feng-
http://www.linkedin.com/in/allenfeng
He has published with Robert Lanza:
For details of the story, see the following link and article:
1. http://www.sciencemag.org/cgi/content/summary/327/5970/1191
2. Qiang Feng, Shijiang Lu, Irina Klimanskaya, Ignatius Gomes, Young Chung, George R Honig, Kwang-Soo Kim, Robert Lanza. Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. Stem Cells 2010 Feb 12. [Epub ahead of print].
WAG MAY 10 2010 8:05 PM
I have no faith that this company will ever be a friend of stockholders, and I fully expect the next RS to clear my remaining shares from SEVA's books. My remaining shares have only been held to remind me how rotten some investments can be.
While I am happy to see a few of the old timers are still here trying to educate anyone who will listen, its unfortunate that many will still fall prey to this companys' siren song...
Should anyone want to learn more about the 'YA' that JimZ noted in his last post, please review this board:
http://investorshub.advfn.com/boards/board.aspx?board_id=9964
RTR - Excellent Find!!!
The TurboEncabulator is now capable of novertrunnions processing.. And, the GirdleSpring (with optional Drawn-Reciprication Dingle Arm) will have the added benefit of soyness soil replacement!
It sounds like this could be exactly what CPRK needs!!
There's only one problem- the price tag.. If CPRK bought one, Obama's prediction for 250 Billion in AS would come true!!!
Richard... go ahead and say it! No offense intended here, but the last time your posts went negative on this stock, the pps shot up! So please, don't hold back!
How bout this tweet:
rlcassidy: RT @RegenMedFdn: Andrew von Eschenbach - former FDA commissioner - Imagine being at the dawn of creation of restoring life processes #trmf10
RTR.. Forget about the one on one's... We should ask the CEO to hold a conference call with all the investors on a regular basis (Monthly or Quarterly). This way we all get our answers at the same time.
As an aside- its nice to see all the new IDs on this board! I hope all the old timers haven't given up on this yet...
Login and Password haven't changed. ogmguest / ogmguest
Common stock authorized- 1,750,000,000 (per Dec 31, 2009 10K)
Stock issued to 4 Officers:
Caldwell.....94,563,717 shares
Lanza........37,192,203 shares
Alan Shapiro.21,783,748 shares
Gary Rabin...12,928,423 shares
....Total...166,468,091
Almost 10% of the common stock for the company has been placed in the hands of these four. The question is- why now?
I worked for 3 public companies over the last 15 years that ended up being acquired. 4-6 months prior to any announcement about the mergers, the officers of these 3 company's got very greedy and granted each other extra helpings of stock options....
OBI... looks like a classic inverted Head and Shoulders you got there. Doesn't that mean that CPRK is ready to rise?
http://www.chartpatterns.com/invtdheadandshoulderschrts.htm
In case anyone cares, here are the sales broken into PPS bands:
PPS ---- Shares Sold - Avg PPS -- Value of Sales
>.03 ---- 22,000,000 - 0.0335 --- $737,000.00
0.02 ---- 10,000,000 - 0.02 ----- $200,000.00
0.01 ---- 97,000,000 - 0.01 ----- $970,000.00
0.005 --- 20,000,000 - 0.005 ---- $100,000.00
0.0038 - 140,500,000 - 0.0038 --- $533,900.00
0.003 -- 130,000,000 - 0.003 ---- $390,000.00
0.0025 - 253,500,000 - 0.0025 --- $633,750.00
0.002 -- 534,250,000 - 0.002 -- $1,068,500.00
"What time period for these sales?"
The dates are not listed for each transaction...
The report only states:
++++++++++++
List of Securities Offerings and Shares Issued for Services in past 2 years
As of September 1, 2008:
Regulation D, 504 Offerings, from December 19, 2007 to August 2009
++++++++++++
Here's the reported count of all the Reg D 504 Sales, including calculation errors (and corrections):
# -- Shares Sold - Price -- Value ----Reported Value - Error in Report
1 --- 15,000,000 - 0.01 --- $150,000
2 --- 12,000,000 - 0.034 -- $408,000
3 --- 10,000,000 - 0.0329 - $329,000
4 ---- 5,000,000 - 0.02 --- $100,000
5 ---- 5,000,000 - 0.02 --- $100,000
6 --- 17,000,000 - 0.01 --- $170,000
7 --- 40,000,000 - 0.01 --- $400,000
8 --- 25,000,000 - 0.01 --- $250,000
9 --- 20,000,000 - 0.005 -- $100,000
10 -- 20,000,000 - 0.0025 -- $50,000 $100,000.00 $50,000.00
11 -- 78,000,000 - 0.0038 - $296,400 $296,000.00 $(400.00)
12 -- 55,000,000 - 0.003 -- $165,000
13 -- 62,500,000 - 0.0038 - $237,500 $187,500.00 $(50,000.00)
14 -- 75,000,000 - 0.002 -- $150,000
15 -- 22,000,000 - 0.002 --- $44,000
16 -- 30,000,000 - 0.002 --- $60,000
17 -- 55,000,000 - 0.002 -- $110,000
18 -- 53,400,000 - 0.002 -- $106,800
19 -- 32,600,000 - 0.002 --- $65,200
20 -- 63,000,000 - 0.002 -- $126,000 $86,000.00 $(40,000.00)
21 -- 28,000,000 - 0.0025 -- $70,000
22 -- 48,000,000 - 0.0025 - $120,000
23 -- 32,500,000 - 0.0025 -- $81,250
24 -- 35,000,000 - 0.0025 -- $87,500
25 -- 37,000,000 - 0.003 -- $111,000
26 -- 38,000,000 - 0.003 -- $114,000
27 -- 26,500,000 - 0.002 --- $53,000
28 - 139,250,000 - 0.002 -- $278,500
29 -- 37,500,000 - 0.002 --- $75,000
30 -- 40,000,000 - 0.0025 - $100,000
31 -- 50,000,000 - 0.0025 - $125,000 Error Totals= $(40,400.00)
Total of Reg D 504 Shares Sold= 1,207,250,000
Avg Price for Reg D 504 Shares= $0.00384
Total Money Raised from Reg D 504 Shares Sold= $4,633,150.00
Total of Reg D 504 + 506 Sales= $104,633,150.00
VVV- I have no trouble opening any of the filings on their website. Also, you can find the same annual filings and a number of quarterly filings at Pinksheets.com.
I would love to see this same level of transparency from CPRK.
Awhile back, I recall reading some concerns with the informed consent requirements, since some original lines may not have all the documents. Any further concerns about that?
+++++++++++++++
The Basics of Eligibility
As in the draft document, the new guidelines clearly spell out how the human embryonic stem cells (hESCs) must have been derived.
The embryo must have been created for reproductive purposes, via in vitro fertilization, must be in excess of clinical need,
and must have been donated voluntarily. Written informed consent for research must have been obtained from the donor(s).
Information about hESC research must have been provided to the donor(s) in a robust informed consent process.
No research involving hESCs derived from a cloned embryo or parthenote (further-developed unfertilized human egg), or created by IVF but specifically for research, will be funded.
Donors cannot have been offered payment either in cash or in kind.
Read the entire policy at:
http://stemcells.nih.gov/policy/2009guidelines.htm
Colorado, You are absolutely correct, FTDs did stop when we went below .01. I went thru every single FTD Report and here is what I found-
First FTD Recorded: Dec 24, 2007 PPS .10
Last FTD Recorded: Jul 29, 2009 PPS .01
Total Trading Days with FTDs Recorded: 331
CPRK had 222 days of recorded FTDs in 2008, when there were only 250 Trading Days.
Total NBR of FTD's Recorded for CPRK: 356,706,925
Median (Average) Number of Daily FTDs: 164,613
Potential Dollar Value of all FTDs:
If held for 10% Gain= $1,035,579
If held for 25% Gain= $2,588,947
If held for 100% Gain= $10,355,790
APR 27, 2009 - Lowest Number of Daily FTDs: 10 (PPS= .02)
JUL 09, 2009 -Highest Number of Daily FTDs: 30,397,304 - (PPS= .01)
If anyone wants a copy of the spreadsheet with all the FTDs for CPRK, send an email with your iHub Alias to: stockibot@yahoo.com
I completely agree with you J4P. The PR's that the company has been putting out don't come close to this fact filled report from Rich. And, his 5 part video lays rest to many BS rumors that are being dumped on the message boards...
Not one offer, but two!
I don't know who was speaking WMH09, but I heard it too..
(starting around the 9:01 mark on the timer)
The speaker says, "a Chinese group came thru about a year and a half ago and wanted to buy the whole thing from Mark and give him a check". Then he said, "they were gonna give him a check for more than what Kennecott was". The tape ended with him saying how Mark politely turned them down, but I couldn't hear why.
Lucky, are you serious? If so, congrats...
CPRK is a producing Copper Mine. Their PPS fell like a rock over the past few weeks due to default on a loan, resulting in a Sheriff's Sale of their mining equipment that was supposed to happen tomorrow. Late today, word is that the Bank and Sheriff's office reported the company worked something out and the sale has been cancelled. Will it run?
Rich, you are the MAN! These are outstanding notes!
Regarding the following notes:
Need input from TerkOH on these next notes as he wrote them:
o 70% up front from broker. Other 30% after weighing and testing.
o 92-93 per truck load
o 40 ton truck load
o 90% iron
o Vert float tanks: (2) 38’ and (2) 20’ 20-30%
o Rougher cells new add 70% something?
o 3700-4800 tons with upgrades
...I understand we may need to wait for additional input from TerkOH, but can you help clarify a couple of things?
1- Is your note; "92-93 per truck load", referring to dollar value?
2- What is the significance of "90% iron"?
3- Is "3700-4800 tons with upgrades" referring to how much ore they will process through the Mill after the upgraded cells are added?
Finally, did you get any sense of when they may achieve their target of multiple truckloads of concentrate shipping each day?
If anyone is interested in the Raser Technologies CEO Conference Call, the URL is:
http://viavid.net/dce.aspx?sid=00006F80
Congrats on all the big winners! Can you guys rub your lucky nickels together and make some magic for CPRK please?
Is this Tom's revenge? He's probably laughing his a$$ off right now! We may see over a BILLION shares traded today...
Its nice to hear that some employees and contractors are getting some of the money they are due. It would be comforting to hear that the company resolved the Sheriff's sale too.
I spoke with a very nice lady in the Records dept of the Sheriff's office about an hour ago and she informed me that the WUCC sale had not been canceled yet
Trav,
These are reports the company provides to the State to show what they have taken from the land and if they have performed any reclamation efforts to improve the land after they are done digging.
For the investor, these reports provide proof of recent mining efforts by the company, while disclosing the quantities of ore being pulled out of the ground at each permitted site. Take a look at post #46821 for more info on their past permits.
I will list the links again to the last two reports from the posts provided by Lucky_1 and me. You will be prompted for a username and password for access to the site. Just use "ogmguest" for both name and password when prompted.
Hidden Treasure and OK mining locations-
https://fs.ogm.utah.gov/FILES/MINERALS/PERMITS/001/M0010067/2010/Incoming/0001.pdf
Bawana mining location-
https://fs.ogm.utah.gov/FILES/MINERALS/PERMITS/001/S0010076/2010/Incoming/0001.pdf
Thanks Lucky_1... There's also a new update for the Bawana Pit:
https://fs.ogm.utah.gov/FILES/MINERALS/PERMITS/001/S0010076/2010/Incoming/0001.pdf
RE: I heard that the whole project got a $100,000,000.00 investment/funding with the first $10,000,000.00 arriving Friday!
...OEM, you posted the following back in July. What gives?
Posted by: OEM Date: Monday, July 13, 2009 2:10:34 PM
In reply to: None Post # of 51774
Found out some interesting stuff for you guys to ponder and rant and rave about tooo.
1. Swiss Bank will possibly become the BIG investor. Millions upon millions of $
2. Price of stock reflects dilution which will end in the coming months.
3. CPRK can't do a reverse split or the SEC shuts them down and does more then we know to the company.
4. CPRK will be buying back shares when the Swiss Bank deal goes through. The means a rocket of a ride.
5. The mine equipment still has clitches, but they run it when they can.
6.Be PATIENT
Since we have no official word from the company and are reduced to our personal opinions, I will express mine...
The issue here is not that MD has become a master of dodging bullets like the one aimed at CPRK right now... It's that he is constantly in this position. He has consistently exhibited disregard for playing by conventional rules (such as- making timely payments on what you owe), which shows complete disrespect for other peoples' money.
I also have a hard time believing that CAM had no knowledge of this. The court hearings prior to this Sheriff's sale would have been in the works for a number of weeks prior to this action.
Is it fair that WE shareholders are not aware of these latest actions until all of our share value has been drained from the market by those in the know? Sorry, but I am feeling scammed here...
On one hand, SLU loans money to the "family" business, and then has to sue for repayment... On the other hand, a member of that family is recognized for helping to provide public funding for SLU.
http://www.watertowndailytimes.com/article/20100114/NEWS05/301149945
"In a statement, college President William L. Fox said, "I'm very grateful for the support of our New York state representatives, Senator Darrel Aubertine, Assemblywoman Addie Jenne Russell and Assemblywoman Dede Scozzafava, for supporting the university in seeking assistance for these projects, which will benefit our students and the community."
Might there be a conflict of interest here?
RE: "Can you say Scozzafava and YA / Cornell ?? YA wants their MONEY......toxic Death Spirals...."
Hopefully both made it onto the list spoken of in this article:
http://www.familysecuritymatters.org/publications/id.5273/pub_detail.asp
RE: Was this Seaway Valley Capital or something once upon a time ?
Yes, HCKI is a SVCC spin off.
IMO, "once upon a time" is appropriate here, since Seaway Valley Capital has a history of "fairy tales with unhappy endings".
Good Luck to anyone involved in this...
Re: Next stop jail stripes
You might be right Mav-
http://www.familysecuritymatters.org/publications/id.5273/pub_detail.asp
INVESTIGATIONAL NEW DRUG APPLICATION
Code of Federal Regulations Part 312:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312
Subpart C covers the "Go / No-Go" process
Don't mean to rehash the topic and I am sorry if this link has already been posted....
The following link will allow you to see all UTAH Mining Permits:
http://www.ogm.utah.gov/fs/mineralsfilesbypermitinfo.php
You will find additional meta data and dates for each of the files easier. You will find 7 permits for Western Utah Copper Company. You still need to use "ogmguest" as the username and password to access the documents.
WUCC shows the following Active and Inactive Permits on file:
M0010059
M0010067
S0010060
S0010061
S0010076
S0010077
S0010078
These records show that Mark Dotson/WUCC has been working on this for a lot longer than most realize.
Updated NIH Stem Cell Registry...
Stem Cell Lines eligible for funding = 40
http://grants.nih.gov/stem_cells/registry/current.htm#registration
Pending Lines = 82
http://grants.nih.gov/stem_cells/registry/pending.htm